Compare Summit Therapeutics Inc (SMMT) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs SoundHound AI Inc — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: Summit Therapeutics Inc is far larger — about 5.6× SoundHound AI Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and SoundHound AI Inc for 23 Days on average.
| SMMT | SOUN | |
|---|---|---|
Market Cap | $13.71B | $2.45B |
Volume | 6,173,057 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $26.38 | $21.40 |
52-Week Low | $12.43 | $5.52 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $13.04B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
SoundHound AI (SOUN) trades at $5.395, down 4.17% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth ($169M in 2025, $203M projected for 2026) but deep net losses (-$14M in 2025, -$137M projected). Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices, positioning for voice AI market growth.
Outlook is mixed: analyst consensus is bullish (75% buy ratings, $9.33 target) on growth prospects, but high valuation (P/S 11.41) and persistent losses pose risks. Key opportunities include market expansion and strategic deals; risks center on profitability, integration challenges, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
